Rapport Therapeutics, Inc. (RAPP) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Rapport Therapeutics, Inc. (RAPP) closed at USD 28.33 on 2026-10-14, a change of -2.2 % over the past year, with a market capitalization of USD 1.42B.
Rapport Therapeutics, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 28.33 |
| 2026-10-13 | 28.99 |
| 2026-10-12 | 30.15 |
| 2026-10-09 | 30.65 |
| 2026-10-08 | 29.85 |
| 2026-10-07 | 30.86 |
| 2026-10-06 | 31.15 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Rapport Therapeutics, Inc. key figures
- Previous close
- USD 28.33 (2026-10-14)
- 1-year change
- -2.2 %
- Market cap
- USD 1.42B
- Enterprise value
- USD 992.75M
- P/E ratio (trailing)
- -9.60
- P/E ratio (forward)
- -5.79
- EPS (trailing)
- -3.08
- EPS (forward)
- -5.11
- PEG ratio
- n/a
- Price to book
- 3.35
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 6.71
- Employees
- 84
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Rapport Therapeutics, Inc. and compare it with other stocks.
Analyze RAPPAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Rapport Therapeutics, Inc. shares.